AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
JERSEY CITY, N.J., March 29, 2017 -- SCYNEXIS, Inc. (NASDAQ:SCYX), a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs, today announced that the Company will present at the 16th Annual Needham Healthcare Conference at The Westin New York Grand Central on Wednesday, April 5, 2017 at 1:40 p.m. ET.
A live webcast will be available on the Investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS is a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
CONTACT: Media Relations Cammy Duong MacDougall Biomedical Communications Tel: 781-591-3443 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 [email protected]
